A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics

The SARS-CoV-2 pandemic has created large demand on global testing capability. Here the authors use the London Biofoundry, an automated synthetic biology platform, and develop an open-source virus-like particle to implement high-throughput diagnostics.

Guardado en:
Detalles Bibliográficos
Autores principales: Michael A. Crone, Miles Priestman, Marta Ciechonska, Kirsten Jensen, David J. Sharp, Arthi Anand, Paul Randell, Marko Storch, Paul S. Freemont
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Q
Acceso en línea:https://doaj.org/article/2a0cbbd782704a1ea3af774cccdeec35
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:2a0cbbd782704a1ea3af774cccdeec35
record_format dspace
spelling oai:doaj.org-article:2a0cbbd782704a1ea3af774cccdeec352021-12-02T17:19:41ZA role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics10.1038/s41467-020-18130-32041-1723https://doaj.org/article/2a0cbbd782704a1ea3af774cccdeec352020-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-18130-3https://doaj.org/toc/2041-1723The SARS-CoV-2 pandemic has created large demand on global testing capability. Here the authors use the London Biofoundry, an automated synthetic biology platform, and develop an open-source virus-like particle to implement high-throughput diagnostics.Michael A. CroneMiles PriestmanMarta CiechonskaKirsten JensenDavid J. SharpArthi AnandPaul RandellMarko StorchPaul S. FreemontNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-11 (2020)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Michael A. Crone
Miles Priestman
Marta Ciechonska
Kirsten Jensen
David J. Sharp
Arthi Anand
Paul Randell
Marko Storch
Paul S. Freemont
A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
description The SARS-CoV-2 pandemic has created large demand on global testing capability. Here the authors use the London Biofoundry, an automated synthetic biology platform, and develop an open-source virus-like particle to implement high-throughput diagnostics.
format article
author Michael A. Crone
Miles Priestman
Marta Ciechonska
Kirsten Jensen
David J. Sharp
Arthi Anand
Paul Randell
Marko Storch
Paul S. Freemont
author_facet Michael A. Crone
Miles Priestman
Marta Ciechonska
Kirsten Jensen
David J. Sharp
Arthi Anand
Paul Randell
Marko Storch
Paul S. Freemont
author_sort Michael A. Crone
title A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
title_short A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
title_full A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
title_fullStr A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
title_full_unstemmed A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
title_sort role for biofoundries in rapid development and validation of automated sars-cov-2 clinical diagnostics
publisher Nature Portfolio
publishDate 2020
url https://doaj.org/article/2a0cbbd782704a1ea3af774cccdeec35
work_keys_str_mv AT michaelacrone aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT milespriestman aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT martaciechonska aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT kirstenjensen aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT davidjsharp aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT arthianand aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT paulrandell aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT markostorch aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT paulsfreemont aroleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT michaelacrone roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT milespriestman roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT martaciechonska roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT kirstenjensen roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT davidjsharp roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT arthianand roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT paulrandell roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT markostorch roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
AT paulsfreemont roleforbiofoundriesinrapiddevelopmentandvalidationofautomatedsarscov2clinicaldiagnostics
_version_ 1718381017061916672